Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Gastrointestinal 1

Conditions

Mesothelioma, Malignant 2Severe combined immunodeficiency with sensitivity to ionizing radiation 1Pancreatic Neoplasms 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 329Cisplatin 276Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 210Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Has results × amatuximab × Clear all
NCT00738582 2022-09-22

Amatuximab

Morphotek

Phase 2 Completed
89 enrolled 12 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT02357147 2020-03-17

ARTEMIS

Morphotek

Phase 2 Terminated
124 enrolled 10 charts
Other solid neoplasmThoracic

Severe combined immunodeficiency with sensitivity to ionizing radiation, Mesothelioma, Malignant

NCT00570713 2015-09-09

An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer

Morphotek

Phase 2 Completed
155 enrolled 12 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡